UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 30, 2015

 

NUTRACEUTICAL INTERNATIONAL CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware
(State of incorporation)

 

000-23731
(Commission
File Number)

 

87-0515089
(IRS Employer
Identification No.)

 

1400 Kearns Boulevard, 2nd Floor
Park City, Utah
(Address of principal executive offices)

 

84060
(Zip Code)

 

Registrant’s telephone number, including area code: (435) 655-6106

 

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 2.02 Results of Operations and Financial Condition.

 

On July 30, 2015, Nutraceutical International Corporation (“Nutraceutical”) reported results for the fiscal 2015 third quarter ended June 30, 2015.  The press release reporting the results is attached to this Form 8-K as Exhibit 99.1.

 

The press release referenced in this Item 2.02, to the extent that it discusses financial results of Nutraceutical for the quarter ended June 30, 2015, is being furnished pursuant to this Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

Nutraceutical herewith files the following documents as exhibits to this Current Report on Form 8-K:

 

(d)     Exhibits

 

Exhibit
Number

 

Description

 

 

 

99.1

 

Press release issued by Nutraceutical dated July 30, 2015

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

NUTRACEUTICAL INTERNATIONAL CORPORATION

 

(Registrant)

 

 

 

By:

/s/ Cory J. McQueen

Date: July 30, 2015

 

 

 

Cory J. McQueen

 

Vice President and Chief Financial Officer

 

(Principal Financial and Accounting Officer)

 

3



 

EXHIBIT INDEX

 

Exhibit
Number

 

Description

99.1

 

Press release issued by Nutraceutical dated July 30, 2015

 

4




Exhibit 99.1

 

FOR:

NUTRACEUTICAL INTERNATIONAL CORPORATION

 

 

CONTACT:

Cory McQueen

 

Vice President and

 

Chief Financial Officer

 

(435) 655-6106

 

NUTRACEUTICAL REPORTS FISCAL 2015 Q3 RESULTS

 

PARK CITY, Utah, July 30, 2015/PRNewswire/—Nutraceutical International Corporation (NASDAQ:  NUTR) today reported results for the fiscal 2015 third quarter ended June 30, 2015.  Net sales for the fiscal 2015 third quarter were $54.4 million compared to $55.6 million for the same quarter of fiscal 2014.  For the third quarter of fiscal 2015, net income was $4.5 million, or $0.47 diluted earnings per share, compared to net income of $4.0 million, or $0.41 diluted earnings per share, for the same quarter of fiscal 2014.

 

Net sales for the nine months ended June 30, 2015 were $162.8 million compared to $162.0 million for the same period of fiscal 2014.  For the nine months ended June 30, 2015, net income was $11.9 million, or $1.24 diluted earnings per share, compared to net income of $12.5 million, or $1.27 diluted earnings per share, for the same period of fiscal 2014.

 

Operating cash flow for the nine months ended June 30, 2015 was $21.2 million compared to $16.1 million for the same period of fiscal 2014.  The operating cash flow for the nine months ended June 30, 2015, combined with existing cash, was primarily used to repay net borrowings of $11.0 million on the Company’s revolving credit facility and to invest $6.5 million in purchases of property, plant and equipment, $3.6 million in purchases of common stock for treasury and $1.3 million in acquisitions of natural product businesses.

 

Bill Gay, chairman and chief executive officer, commented, “Our Adjusted EBITDA, net income and operating cash flow for the third quarter of fiscal 2015 strengthened. The decrease in fiscal 2015 third quarter net sales of 2.2% was primarily related to international customers and, to a lesser extent, private label accounts.  International sales continued to be impacted negatively by the stronger U.S. dollar and fewer orders from certain international customers. Our focus on only purchasing the highest quality raw materials means that sourcing and related out-of-stocks continued to be a challenge for our manufacturing operations. Management believes that ongoing synergies from acquisitions and operational changes that have been implemented will enhance our overall results by the end of this calendar year.”

 



 

Mr. Gay stated, “Our operating cash flow provided the financial resources required to re-purchase stock, make capital investments, pay down debt and acquire competitive businesses.  Management seeks to acquire niche companies that fill gaps in our existing product coverage.  Acquisitions remain a key component to our long-term growth.”

 

Mr. Gay continued, “Larger natural food market chains continue their roll-out in most major US markets.  This is requiring the smaller and medium sized health food stores to become more competitive in order to prosper or even survive.  While we continue our historical support of these independent health food stores, some are not responding quickly enough and are struggling and facing the choice of closing or selling locations. This is resulting in a pronounced shift of customers to larger natural food stores.  Fortunately, the growth of these larger chains seems to be offsetting corresponding declines in smaller stores.  We believe that the size and breadth of our brand and product offering should enable us to continue to be a primary supplier for larger stores and that we are positioned to capitalize on this changing marketplace.  Management would like to express our appreciation and thanks to our employees and stakeholders for their ongoing support of our company’s long-term growth goals.”

 

ABOUT NUTRACEUTICAL

 

We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores.  Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers.  Our core business strategy is to acquire, integrate and operate businesses in the natural products industry that manufacture, market and distribute branded nutritional supplements.  We believe that the consolidation and integration of these acquired businesses provide ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.

 

We manufacture and sell nutritional supplements and other natural products under numerous brands, including Solaray®, KAL®, Nature’s Life®, LifeTime®, Natural Balance®, NaturalCare®, Health from the Sun®, Pioneer®, Nutra BioGenesis™, Life-flo®, Organix South®, Heritage Store® and Monarch Nutraceuticals™.

 

We own neighborhood natural food markets, which operate under the trade names The Real Food Company™, Thom’s Natural Foods™, Cornucopia Community Market™ and Granola’s™.

 



 

We also own health food stores, which operate under various trade names, including Fresh Vitamins™ and Peachtree Natural Foods®.

 

We manufacture and/or distribute one of the broadest branded product lines in the industry with over 8,000 SKUs, including approximately 800 SKUs exclusively sold internationally.  We believe that as a result of our emphasis on innovation, quality, loyalty, education and customer service, our brands are widely recognized in health and natural food stores and among their customers.

 

This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terms such as “believe,” “expects,” “plan,” “intend,” “may,” “will,” “should,” “can,” or “anticipates,” or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause industry trends or our actual results to be materially different from any future results expressed or implied by these statements.  Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to: (i) changes in or new government regulations or increased enforcement of the same; (ii) unavailability of desirable acquisitions, inability to complete them or inability to integrate them; (iii) increased costs, including from increased raw material or energy prices; (iv) changes in general worldwide economic or political conditions; (v) adverse publicity or negative consumer perception regarding nutritional supplements; (vi) issues with obtaining raw materials of adequate quality or quantity; (vii) litigation and claims, including product liability, intellectual property and other types;  (viii) disruptions from or following acquisitions including the loss of customers; (ix) increased competition; (x) slow or negative growth in the nutritional supplement industry or the healthy foods channel; (xi) the loss of key personnel or the inability to manage our operations efficiently; (xii) problems with information management systems, manufacturing efficiencies and operations; (xiii) insurance coverage issues; (xiv) the volatility of the stock market generally and of our stock specifically; (xv) increases in the cost of borrowings or unavailability of additional debt or equity capital, or both, or fluctuations in foreign currencies; and (xvi) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest and other factors outside of our control.  Copies of our SEC reports are available upon request from our investor relations department or may be obtained at the SEC’s website (www.sec.gov).

 

# # #

 



 

NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited; dollars in thousands)

 

 

 

June 30,

 

September 30,

 

 

 

2015

 

2014

 

Assets

 

 

 

 

 

Current assets, net

 

$

82,425

 

$

83,850

 

Property, plant and equipment, net

 

78,350

 

79,244

 

Goodwill

 

24,384

 

23,622

 

Other non-current assets, net

 

25,746

 

28,062

 

 

 

$

210,905

 

$

214,778

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

Current liabilities

 

$

20,070

 

$

21,709

 

Long-term liabilities

 

32,171

 

43,456

 

Stockholders’ equity

 

158,664

 

149,613

 

 

 

$

210,905

 

$

214,778

 

 



 

NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited; dollars in thousands, except per share data)

 

 

 

Three months ended June 30,

 

Nine months ended June 30,

 

 

 

2015

 

2014

 

2015

 

2014

 

Net sales

 

$

54,382

 

$

55,625

 

$

162,830

 

$

162,034

 

Cost of sales

 

27,955

 

28,473

 

83,293

 

81,660

 

Gross profit

 

26,427

 

27,152

 

79,537

 

80,374

 

Operating expenses

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

19,061

 

19,762

 

58,404

 

57,625

 

Amortization of intangible assets

 

729

 

704

 

2,189

 

1,940

 

Income from operations

 

6,637

 

6,686

 

18,944

 

20,809

 

Interest and other expense, net

 

257

 

356

 

827

 

1,024

 

Income before provision for income taxes

 

6,380

 

6,330

 

18,117

 

19,785

 

Provision for income taxes

 

1,930

 

2,333

 

6,220

 

7,329

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

4,450

 

$

3,997

 

$

11,897

 

$

12,456

 

 

 

 

 

 

 

 

 

 

 

Net income per common share

 

 

 

 

 

 

 

 

 

Basic

 

$

0.47

 

$

0.41

 

$

1.24

 

$

1.27

 

Diluted

 

0.47

 

0.41

 

1.24

 

1.27

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

 

 

 

 

 

 

 

 

Basic

 

9,561,008

 

9,798,393

 

9,612,171

 

9,826,516

 

Diluted

 

9,563,999

 

9,806,793

 

9,617,091

 

9,835,666

 

 



 

NUTRACEUTICAL INTERNATIONAL CORPORATION

ADJUSTED EBITDA SCHEDULE

(unaudited; dollars in thousands)

 

 

 

Three months ended June 30,

 

Nine months ended June 30,

 

 

 

2015

 

2014

 

2015

 

2014

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

4,450

 

$

3,997

 

$

11,897

 

$

12,456

 

Provision for income taxes

 

1,930

 

2,333

 

6,220

 

7,329

 

Interest and other expense, net (1)

 

257

 

356

 

827

 

1,024

 

Depreciation and amortization

 

3,195

 

2,942

 

9,702

 

8,357

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

$

9,832

 

$

9,628

 

$

28,646

 

$

29,166

 

 


(1)   Includes amortization of deferred financing fees.

 

Non-GAAP Financial Measures

 

Adjusted EBITDA (a non-GAAP measure) is defined in our performance measures as earnings before net interest and other expense, taxes, depreciation, amortization and goodwill and intangible asset impairments.  We believe that Adjusted EBITDA provides useful additional information to analysts, creditors, investment bankers and management regarding operating performance and debt covenant compliance.  Adjusted EBITDA has some inherent limitations in measuring operating performance due to the exclusion of certain financial elements such as depreciation and amortization and is not necessarily comparable to other similarly-titled captions of other companies due to potential inconsistencies in the method of calculation.  Furthermore, Adjusted EBITDA is not intended to be an alternative to net income in determining our operating performance in accordance with generally accepted accounting principles.

 


Nutraceutical International Corp. (MM) (NASDAQ:NUTR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Nutraceutical International Corp. (MM) Charts.
Nutraceutical International Corp. (MM) (NASDAQ:NUTR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Nutraceutical International Corp. (MM) Charts.